Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The DUSP6-RSK1 pathway: a driver of disease progression in MPNs

Stephen Oh • 27 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms

Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses the promise of targeting the DUSP6-RSK1 pathway in myeloproliferative neoplasms (MPNs), which has shown to be a driver of disease progression. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Stephen Oh

Leveraging inflammatory cytokine signaling for therapeutic benefit in MPNs
Stephen Oh • 24 Nov 2022
Targeting an aberrant DUSP6-RSK1 signaling axis driving MPN disease development & progression
Stephen Oh • 10 Nov 2022
1:07
Signaling pathways activated in MPNs: targeting the DUSP6-RSK1 pathway
Stephen Oh • 27 Aug 2022
3:25
Targeting dysregulated signaling networks for the treatment of MPNs
Stephen Oh • 12 Aug 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals